Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells
Deepak Bhere,Sung Hugh Choi,Pim van de Donk,David Hope,Kiki Gortzak,Amina Kunnummal,Jasneet Khalsa,Esther Revai Lechtich,Clemens Reinshagen,Victoria Leon,Nabil Nissar,Wenya Linda Bi,Cheng Feng,Hongbin Li,Yu Shrike Zhang,Steven H. Liang,Neil Vasdev,Walid Ibn Essayed,Pablo Valdes Quevedo,Alexandra Golby,Naima Banouni,Anna Palagina,Reza Abdi,Brian Fury,Stelios Smirnakis,Alarice Lowe,Brock Reeve,Arthur Hiller,E. Antonio Chiocca,Glenn Prestwich,Hiroaki Wakimoto,Gerhard Bauer,Khalid Shah
DOI: https://doi.org/10.1038/s41467-022-30558-3
IF: 16.6
2022-05-19
Nature Communications
Abstract:Abstract Cellular therapies offer a promising therapeutic strategy for the highly malignant brain tumor, glioblastoma (GBM). However, their clinical translation is limited by the lack of effective target identification and stringent testing in pre-clinical models that replicate standard treatment in GBM patients. In this study, we show the detection of cell surface death receptor (DR) target on CD146-enriched circulating tumor cells (CTC) captured from the blood of mice bearing GBM and patients diagnosed with GBM. Next, we developed allogeneic “off-the-shelf” clinical-grade bifunctional mesenchymal stem cells (MSC Bif ) expressing DR-targeted ligand and a safety kill switch. We show that biodegradable hydrogel encapsulated MSC Bif (EnMSC Bif ) has a profound therapeutic efficacy in mice bearing patient-derived invasive, primary and recurrent GBM tumors following surgical resection. Activation of the kill switch enhances the efficacy of MSC Bif and results in their elimination post-tumor treatment which can be tracked by positron emission tomography (PET) imaging. This study establishes a foundation towards a clinical trial of EnMSC Bif in primary and recurrent GBM patients.
multidisciplinary sciences